Page last updated: 2024-08-23

etoposide and unc 0638

etoposide has been researched along with unc 0638 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agarwal, P; Jackson, SP	1

Other Studies

1 other study(ies) available for etoposide and unc 0638

Article	Year
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status. Cancer letters, 2016, 10-01, Volume: 380, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HCT116 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplasms; Phleomycins; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Transfection; Tumor Suppressor Protein p53	2016

Article

Year

G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.

Cancer letters, 2016, 10-01, Volume: 380, Issue:2

Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HCT116 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplasms; Phleomycins; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Transfection; Tumor Suppressor Protein p53

2016